Business
Result of Annual General Meeting
Abingdon Health plc announced that at its Annual General Meeting held on December 10, 2025, all resolutions were passed with overwhelming support, receiving over 99.7% of votes in favour, indicating strong shareholder confidence in the company's direction and management. Disclaimer*

About this update from Abingdon Health Plc
Abingdon Health plc ("Abingdon Health", the "Group" or the "Company") Result of Annual General Meeting York, UK 10 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed with greater than 99.7% of votes in favour. Enquiries: Abingdon Health plc www.abingdonhealth.com/investors/ Chris Hand, Executive Chairman Via Walbrook PR T om Hayes, CFO Zeus (Sole Broker and Nominated Adviser) Tel: +44 (0)20 3829 5000 Antonio Bossi / Jacob Walker (Corporate Finance) Walbrook PR (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or [email protected] Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 About Abingdon Health Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base. The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success. Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities. Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA. Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com .
View stock analysis, news, and events for Abingdon Health Plc